Protac Targeted Protein Degradation Therapy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Protac Targeted Protein Degradation Therapy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
PROTACs (Proteolysis-Targeting Chimeras) are bifunctional molecules that harness the cell's own [ubiquitin-proteasome system](/cell-types/ubiquitin-proteasome-system) to selectively degrade disease-causing proteins. This represents a paradigm shift from traditional inhibition to actual elimination of target proteins. A single PROTAC molecule can degrade multiple target proteins through catalytic activity. ## Mechanism of Action
Molecular Glue Mechanism
PROTACs work through a three-step process:
Binding: The PROTAC molecule binds simultaneously to:
A target protein (e.g., mutant [huntingtin](/genes/htt), [tau](/proteins/tau), α-synuclein)
An E3 ubiquitin ligase (cereblon, VHL, MDM2, cIAP1)
Ubiquitination: The proximity of the target protein to the E3 ligase leads to polyubiquitination
Degradation: The tagged protein is recognized and degraded by the 26S proteasome
Key Advantages
Catalytic activity: Substoichiometric dosing
Undruggable targets: Can target proteins lacking active sites
Temporal control: Protein levels reducible without complete knockout ## Disease-Specific Applications
Huntington's Disease
HTTex1 (mutant huntingtin exon 1): Primary target
B6H10 and Dheb compounds show efficacy in mouse models
Alzheimer's Disease
[Tau](/proteins/tau) protein degradation: Multiple PROTACs in development
Resistance: Mutations in target or E3 ligase ## Emerging Technologies
Molecular Glues
Smaller than traditional PROTACs
Better pharmacokinetics
Examples: thalidomide derivatives, indisulam
AUTAC (Autophagy-Targeting Chimeras)
Target proteins for autophagic degradation
Can degrade organelles and protein aggregates
LYTAC (Lysosome-Targeting Chimeras)
Degrade extracellular and membrane proteins
Use lysosomal trafficking receptors
Background
The study of Protac Targeted Protein Degradation Therapy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[Nature Reviews Drug Discovery - PROTACs](https://www.nature.com/articles/s41573-022-00574-5)
References
Sakamoto KM, Kim KB, Kumagai A, et al, Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation (2001)
Tomoshige S, Nomura S, Ohgane K, Hashimoto Y, Ishikawa M, Small molecules that promote degradation of mutant huntingtin protein (2017)
Chirnomas D, Hornberger KR, Protein degraders enter the clinic - a new approach to drug discovery (2023)
Wang C, Zhang Y, Wu J, Xing D, Development of PROTAC-based targeted protein degradation for Alzheimer's disease (2022)
Takahashi Y, Miyamoto N, Shinkai S, et al, Discovery of a small molecule PROTAC that selectively degrades mutant huntingtin protein (2022)
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate